MEDICATION SAFETY

FDA revises prescribing information, container labels for HYDROmorphone

This summer, FDA approved revisions to the prescribing information and container labels for HYDROmorphone HCl (Dilaudid, Purdue Pharma), because of serious medication errors caused by confusing labels and information. » More

CONTINUING EDUCATION

Update on REMS associated with long-acting opioids

In carrying out Risk Evaluation and Mitigation Strategies associated with long-acting opioids, the pharmacist plays a multidimensional role in this effort, which includes educating patients, prescribers, and the community at large, being vigilant to signs of overprescribing or abuse, and recognizing the biopsychosocial factors that put pain patients at risk for substance abuse. Click here to login and take the exams.

Resource Center: Oral Anticoagulation in Atrial Fibrillation

Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies, click here.

PREVENTION STRATEGIES

Common healthcare facility infections declined in 2010, data shows

The common infections seen in healthcare facilities declined in 2010, according to the CDC. » More

CDC launches prevention program for cancer patients, caregivers

The CDC has launched an interactive website and educational program for cancer patients and their caregivers to help prevent infections in patients while they are undergoing chemotherapy. » More

CLINICAL NEWS

Lilly announces withdrawal of septic shock treatment following clinical trial results

Eli Lilly and Company has announced a worldwide withdrawal of its drotrecogin alfa (activated) (Xigris) in all markets following results of the PROWESS-SHOCK study, regarding patients with septic shock. » More

ACIP votes for expanded use of HPV vaccine in boys, young men

The CDC's ACIP voted to recommend that boys aged 11 to 12 years be vaccinated routinely with human papillomavirus (HPV) quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant (Gardasil, Merck) to help prevent cancer and other diseases caused by HPV. » More

FDA ACTIONS

FDA approves first generic olanzapine to treat schizophrenia, bipolar disorder

FDA has approved the first generic versions of Zyprexa (olanzapine tablets) and Zyprexa Zydus (olanzapine orally disintegrating tablets) to treat schizophrenia and bipolar disorder. » More

FDA approves clobazam to treat severe type of seizures

FDA has approved clobazam (Onfi, Lundbeck and Catalent Pharma Solutions) as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	Anticoagulation update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.